Vanessa Mizak
Nurse Practitioner · Corvallis, ORNPI 1669860979
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,231 and has fallen 90.7% since, to $114 in 2025. Among nurse practitioner clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $24.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$681
- United Therapeutics Corporation$660
- Regeneron Healthcare Solutions, Inc.$369
- Boehringer Ingelheim$302
- Baxter Healthcare$176
- Sanofi$173
- plus $974 from 16 others
What the payments were for
- Food & beverage$3,16795%
- Education$1685%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 25 | $681 |
| United Therapeutics Corporation | 21 | $660 |
| Regeneron Healthcare Solutions, Inc. | 10 | $369 |
| Boehringer Ingelheim | 9 | $302 |
| Baxter Healthcare | 15 | $176 |
| Sanofi | 8 | $173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $166 |
| Insmed, Inc. | 6 | $111 |
| Actelion Pharmaceuticals US, Inc. | 4 | $108 |
| Grifols USA, LLC | 6 | $100 |
| Mylan Specialty L.p. | 4 | $82 |
| GSK | 5 | $77 |
| Philips North America LLC | 4 | $64 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Amgen | 3 | $53 |
| Merck | 1 | $33 |
| Medtronic | 1 | $27 |
| Novartis | 1 | $22 |
| Bayer | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Pulmonx Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,336 in reported general payments places this provider in the 95th percentile of 997 nurse practitioner providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 820 | $654,399 |
| UptraviSelexipag | 14 | $332,864 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 252 | $196,488 |
| Dupixent PenDupilumab | 39 | $141,573 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 199 | $116,603 |
| TezspireTezepelumab-Ekko | 28 | $116,085 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 130 | $86,446 |
| Spiriva RespimatTiotropium Bromide | 112 | $85,280 |
| Ambrisentan | 35 | $69,324 |
| Breo ElliptaFluticasone/Vilanterol | 108 | $54,308 |
| Advair HfaFluticasone Propion/Salmeterol | 90 | $45,939 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 49 | $29,031 |
| Incruse ElliptaUmeclidinium Bromide | 51 | $23,950 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 465 | $17,632 |
| SymbicortBudesonide/Formoterol Fumarate | 49 | $17,402 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $77 | $860,4751,216 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi | $108 | $332,86414 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $681 | $329,975329 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $302 | $200,757291 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Albuterol Sulfate | $18 | $8,37031 claims |
| MerckDulera | $33 | $7,93718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 997 nurse practitioner providers in Oregon.
Other nurse practitioner in Corvallis
- Holly AlmondCorvallis$4K
- Nicole FisherCorvallis$4K
- Alicia DuyvejonckSpringfield$299K
- Summer HarnessLake Oswego$113K
- Alana WilsonPortland$58K
- Jennifer MurdochPortland$15K
- Berhane MebratuPortland$10K
- Desiree CihelkaSpringfield$8K
- Amy CarterPortland$8K
- Margaret McLainCoos Bay$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.